MAPT and Alzheimer disease: Knockdown of GSAP in an AD model transgenic mice (APPsweXPS1ΔE9) reduces Aβ burden (He et al., 2010) and treatment with imatinib, which binds to GSAP, reduces GSAP expression, Aβ levels, and tau phosphorylation in another AD mouse model (3xTg; Chu et al., 2014).